Skip to main content

Advertisement

SpringerLink
Log in

Inflammatory demyelinating neuropathies

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Early and effective treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) is important to minimize axonal degeneration that occurs secondary to demyelination. The disease course is invariably chronic, so long-term treatment is often required, and adverse effects and costs are important considerations in devising a treatment plan. CIDP responds to prednisone, but long-term treatment can result in significant adverse effects. Azathioprine, mycophenolate mofetil, and cyclosporine can be used as steroid-sparing agents and may facilitate more rapid and successful tapering of prednisone. Intravenous immunoglobulin (IVIg) and plasma exchange are also effective in the treatment of CIDP and can be used in patients who are unresponsive to prednisone or develop steroid-related adverse effects. IVIg may also be used as a first-line treatment, but its cost can be a limiting factor. A few uncontrolled studies have suggested that pulsed weekly methylprednisolone is both effective and well tolerated in the long-term treatment of CIDP. Treatments based on rituximab or cyclophosphamide have also been used in resistant disease.

Variants of CIDP have been described on the basis of their association with specific antibodies or immunoglobulins and their response to specific immunomodulatory treatments. Multifocal motor neuropathy with conduction block responds to IVIg in the majority of patients. However, weakness may slowly worsen over time, and some patients become unresponsive. Anecdotal reports suggest that rituximab may be useful in patients who develop progressive disease.

Placebo-controlled trials in anti-myelin-associated glycoprotein neuropathy suggest that rituximab is effective and, with a combination of prednisone and cyclophosphamide, numbness and strength may improve. Other treatments that may be effective include plasma exchange and IVIg. Treatment is generally started with prednisone, IVIg, or plasma exchange. Rituximab and cyclophosphamide are used only in progressive, treatment-resistant disease because of the potential for serious adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hughes R, Bensa S, Willison H, et al.: Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001, 50:195–201.

    Article  PubMed  CAS  Google Scholar 

  2. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Neurology 1991, 41:617–618.

  3. Lewis RA, Sumner AJ, Brown MJ, Asbury AK: Multifocal demyelinating neuropathy with persistent conduction block. Neurology 1982, 32:958–964.

    PubMed  CAS  Google Scholar 

  4. Delmont E, Azulay JP, Giorgi R, et al.: Multifocal motor neuropathy with and without conduction block: a single entity? Neurology 2006, 67:592–596.

    Article  PubMed  CAS  Google Scholar 

  5. Slee M, Selvan A, Donaghy M: Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology 2007, 69:1680–1687.

    Article  PubMed  Google Scholar 

  6. Hughes RA, Donofrio P, Bril V, et al.: Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebocontrolled trial. Lancet Neurol 2008, 7:136–144.

    Article  PubMed  CAS  Google Scholar 

  7. Hahn AF, Bolton CF, Pillay N, et al.: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996, 119:1055–1066.

    Article  PubMed  Google Scholar 

  8. Hahn AF, Bolton CF, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebocontrolled, cross-over study. Brain 1996, 119:1067–1077.

    Article  PubMed  Google Scholar 

  9. Lopate G, Pestronk A, Al-Lozi M: Treatment of chronic inflammatory demyelinating polyneuropathy with highdose intermittent intravenous methylprednisolone. Arch Neurol 2005, 62:249–254.

    Article  PubMed  Google Scholar 

  10. Muley SA, Kelkar P, Parry GJ: Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids. Arch Neurol 2008, 65:1460–1464.

    Article  PubMed  Google Scholar 

  11. Hodgkinson SJ, Pollard JD, McLeod JG: Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 1990, 53:327–330.

    Article  PubMed  CAS  Google Scholar 

  12. Gorson KC, Amato AA, Ropper AH: Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004, 63:715–717.

    PubMed  CAS  Google Scholar 

  13. Good JL, Chehrenama M, Mayer RF, Koski CL: Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998, 51:1735–1738.

    PubMed  CAS  Google Scholar 

  14. Brannagan TH 3rd, Pradhan A, Heiman-Patterson T, et al.: High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002, 58:1856–1858.

    PubMed  CAS  Google Scholar 

  15. Gorson KC, Natarajan N, Ropper AH, Weinstein R: Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007, 35:66–69.

    Article  PubMed  CAS  Google Scholar 

  16. Viala K, Renie L, Maisonobe T, et al.: Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain 2004, 127:2010–2017.

    Article  PubMed  CAS  Google Scholar 

  17. Saperstein DS, Amato AA, Wolfe GI, et al.: Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 1999, 22:560–566.

    Article  PubMed  CAS  Google Scholar 

  18. Leger JM, Chassande B, Musset L, et al.: Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 2001, 124:145–153.

    Article  PubMed  CAS  Google Scholar 

  19. Nobile-Orazio E, Cappellari A, Meucci N, et al.: Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block. J Neurol Neurosurg Psychiatry 2002, 72:761–766.

    Article  PubMed  CAS  Google Scholar 

  20. Carpo M, Cappellari A, Mora G, et al.: Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 1998, 50:1480–1482.

    PubMed  CAS  Google Scholar 

  21. Ruegg SJ, Fuhr P, Steck AJ: Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 2004, 63:2178–2179.

    PubMed  Google Scholar 

  22. Niermeijer JM, Eurelings M, van der Linden MW, et al.: Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology 2007, 69:50–59.

    Article  PubMed  CAS  Google Scholar 

  23. Benedetti L, Briani C, Grandis M, et al.: Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 2007, 12:102–107.

    Article  PubMed  CAS  Google Scholar 

  24. Kilidireas C, Anagnostopoulos A, Karandreas N, et al.: Rituximab therapy in monoclonal IgM-related neuropathies. Leuk Lymphoma 2006, 47:859–864.

    Article  PubMed  CAS  Google Scholar 

  25. Levine TD, Pestronk A: IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999, 52:1701–1704.

    PubMed  CAS  Google Scholar 

  26. Gorson KC, Ropper AH, Weinberg DH, Weinstein R: Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve 2001, 24:778–786.

    Article  PubMed  CAS  Google Scholar 

  27. Hughes RA, Swan AV, van Doorn PA: Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2004, 4: CD003280.

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Minnesota, Minneapolis, MN, 55455, USA

    Suraj Ashok Muley

Authors
  1. Suraj Ashok Muley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gareth J. Parry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suraj Ashok Muley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Muley, S.A., Parry, G.J. Inflammatory demyelinating neuropathies. Curr Treat Options Neurol 11, 221–227 (2009). https://doi.org/10.1007/s11940-009-0026-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-009-0026-4

Keywords

Search

Navigation